Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02963428
Other study ID # 2016-0205
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date July 2019

Study information

Verified date August 2019
Source Geisinger Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to improve obstetrical care by managing gestational weight gain (GWG) among high risk women in an effort to reduce maternal and fetal complications.


Description:

The project is aimed at teaching women about the appropriate weight gain during pregnancy to optimize health outcomes for mothers and newborn babies. Obese gravida meeting inclusion criteria and none of the exclusion criteria will be offered enrollment in TAGG. Those that consent will be randomized to receive standard of care or enhanced care regarding gestational weight gain.

The primary outcome is the proportion of patients that gain less than 20 lbs over the course of the pregnancy. Secondary outcomes include patient knowledge and expectations, attitude about pregnancy weight gain, self-efficacy of ability to eat healthy, and eating, sleeping and physical activity behavior, perceived stress, psychological factors, patient-experience, involvement in care, and food security.


Recruitment information / eligibility

Status Completed
Enrollment 218
Est. completion date July 2019
Est. primary completion date July 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Pre-pregnancy body mass index of at least 30 kg/m2 (per patient report of weight)

- Less than 16 weeks gestation

- Gestational weight gain (GWG) less than < 11 pounds from their pre-pregnancy weight to time of potential study enrollment

- Singleton gestation

- Access to a phone

Exclusion Criteria:

- BMI less than 30 kg/m2

- Gestational age greater than or equal to 16 weeks

- Active diagnosis of cancer on their electronic health record problem list

- Acquired immunodeficiency syndrome (AIDS)

- Palliative medicine patients

- Multiple gestations

- GWG in excess of 11 pounds prior to study enrollment

- Patients with Non-Geisinger prenatal care providers

- Vegan diet

- Malabsorptive conditions

- Previously enrolled in TAGG during prior pregnancy. Patient will be excluded from re-randomization

- Non-English Speaking

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Enhanced Care
In addition to standard of care, the study participants will also receive: i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy.

Locations

Country Name City State
United States Geisinger Health System Danville Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Geisinger Clinic Penn State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gestational weight gain, adjusting for time in the study at delivery
Secondary Patient knowledge and expectations factors Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs. This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient knowledge and expectations factors. Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
Secondary Attitude on pregnancy weight gain Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs. This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient attitudes on pregnancy weight gain. Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
Secondary Self-efficacy of healthy eating Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs. This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient self-efficacy of healthy eating. Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
Secondary Eating, sleeping and physical activity behavior Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs. This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient eating, sleeping and physical activity behaviors. Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
Secondary Patient-experience and involvement in care Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs. This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient experience and involvement in their care. Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
Secondary Delivery of large for gestational age infants This measure will be obtained using electronic health record data and analyzed utilizing clinic data points as well as information gathered from patients through self-report survey data. At Delivery
Secondary Diagnosis of gestational diabetes mellitus This measure will be obtained using EHR data and analyzed utilizing clinic data points. Baseline through 4-12 Weeks Postpartum
Secondary Neonatal intensive care unit (NICU) admissions At Delivery
Secondary Cost of Treatment Participant cost of treatment will be assessed utilizing claims data obtained from Geisinger Health Plan to compare the effectiveness of the intervention in reducing cost. Baseline through 4-12 Weeks Postpartum
Secondary Mode of delivery Clinical electronic health record data in regards to the participant mode of delivery will be utilized in statistical analyses to determine whether mode of delivery has an impact on other outcomes of interest. At Delivery
Secondary Rate of gestational weight gain Baseline through 4-12 weeks postpartum
Secondary Perceived stress measured via Perceived Stress Scale Perceived Stress will be measured using the Perceived Stress Scale by Cohen et. al. Baseline through 4-12 weeks postpartum
Secondary Psychological factors measured via Pregnancy Weight Gain Attitude Scale Psychological factors will be assessed using the Pregnancy Weight Gain Attitude Scale by Palmer et. al. Baseline through 4-12 Weeks postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2